Ask AI
ProCE Banner Series

Applying Evidence to Implement New and Novel Therapy in the Management of Myelofibrosis

Join us for a live, interactive, 1-hour ACPE-certified webinar featuring expert perspectives on current best practices and emerging strategies in managing patients with myelofibrosis. Bring your questions for the live Q&A session with the expert panel at the end of the presentation.

In coordination with HOPA's Annual Conference

  ACPE-P
Credits Available

1.0

Who Should Attend

The target audience is pharmacists who care for patients with myelofibrosis and other stakeholders in hematology/oncology practice

All Events

Applying Evidence to Implement New and Novel Therapy in the Management of Myelofibrosis

Past Events

May

25

2023

3:00 PM - 4:00 PM Eastern Time (ET)

Virtual

Topics

  • Introduction and overview
  • Risk assessment and symptom scoring for MF
  • Key concepts in the use of JAK inhibitors to treat patients with MF
  • Novel treatment strategies for patients with ruxolitinib failure, anemia, and/or thrombocytopenia
  • Practical elements in pharmacy
  • Audience question and answer session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with myelofibrosis.

Target Audience
The target audience is pharmacists who care for patients with myelofibrosis and other stakeholders in hematology/oncology practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Interpret clinical efficacy and safety data to develop individualized treatment plans for patients with myelofibrosis
  • Recommend evidence-based treatment plan for suboptimal response or loss of response to first-line therapy
  • Devise prevention, mitigation, and management strategies for medication-related adverse events for second-line and novel therapies for myelofibrosis
  • Communicate with caregivers and patients regarding their disease, symptoms, and treatment options

Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-015-L01-P has been assigned to this live application-based activity (initial release date 5/24/2023). This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC and the Hematology/Oncology Pharmacy Association (HOPA)

Supported by an educational grant from GSK.

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191